Latest & greatest articles for tiotropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tiotropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tiotropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tiotropium

61. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease. 18836213 2008 10 09 2008 10 28 2015 11 19 1533-4406 359 15 2008 Oct 09 The New England journal of medicine N. Engl. J. Med. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. 1543-54 10.1056/NEJMoa0805800 Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term effects of tiotropium therapy (...) . In this randomized, double-blind trial, we compared 4 years of therapy with either tiotropium or placebo in patients with COPD who were permitted to use all respiratory medications except inhaled anticholinergic drugs. The patients were at least 40 years of age, with a forced expiratory volume in 1 second (FEV(1)) of 70% or less after bronchodilation and a ratio of FEV(1) to forced vital capacity (FVC) of 70% or less. Coprimary end points were the rate of decline in the mean FEV(1) before and after

NEJM2008

63. Short-acting bronchodilators added to maintenance tiotropium therapy.

Short-acting bronchodilators added to maintenance tiotropium therapy. BACKGROUND: Combining bronchodilators has been shown to be beneficial in patients with COPD. The additive effects of short-acting bronchodilators added to maintenance tiotropium therapy, however, are unknown. METHODS: Following 3 weeks of tiotropium pretreatment, 60 patients with COPD (FEV1 40% of predicted) participated in a randomized, placebo-controlled study to assess add-on bronchodilator effects of ipratropium bromide (...) (40 microg) or fenoterol (200 microg). Short-acting bronchodilators were added as a single dose 2 h and 8 h after tiotropium dosing. Serial lung function tests were performed over 9 h. RESULTS: The peak FEV1 add-on response within 6 h with fenoterol was significantly greater than with placebo (137 mL) or ipratropium (84 mL); the response with ipratropium was slightly but significantly larger than with placebo (52 mL). One hour after the second dose of the test drugs, a similar order of treatment

EvidenceUpdates2007

64. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis

Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis Rodrigo G J, Nannini L J CRD summary This review concluded that the use of tiotropium was beneficial in treatment of patients with moderate (...) -to-severe stable chronic obstructive pulmonary disease. Previous evidence in favour of the superiority of tiotropium over long-acting beta-agonists was also supported. As the results may not be generalisable and potential bias was possible, these conclusions may not be reliable. Authors' objectives To update the evidence of the effectiveness of tiotropium bromide for the treatment of stable chronic obstructive pulmonary disease patients. Searching Searches were performed in MEDLINE (1966-2006), EMBASE

DARE.2007

65. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Rutten-van Molken M P, Oostenbrink J B (...) , Miravitlles M, Monz B U Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study considered three bronchodilators for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Specifically, tiotropium (a long-acting

NHS Economic Evaluation Database.2007

66. Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life

Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Article Text Therapeutics Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Free Matthew B Stanbrook , MD, PhD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

67. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore Lee K H, Phua J, Lim T K Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to perform a pharmacoeconomic analysis on the treatment of chronic obstructive pulmonary disease (COPD) with the addition of tiotropium bromide. The authors concluded that adding

NHS Economic Evaluation Database.2006

68. Spiriva HandiHaler (Tiotropium Bromide) Inhalation Powder

Spiriva HandiHaler (Tiotropium Bromide) Inhalation Powder Drug Approval Package: Spiriva HandiHaler (Tiotropium Bromide) NDA #021395 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Spiriva HandiHaler (Tiotropium Bromide) Inhalation Powder Company: Boehringer Ingelheim Application No.: 021395 Approval Date: 1/30/2004 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2004

69. Tiotropium: a potential replacement for ipratropium in patients with COPD

Tiotropium: a potential replacement for ipratropium in patients with COPD Tiotropium: a potential replacement for ipratropium in patients with COPD Tiotropium: a potential replacement for ipratropium in patients with COPD Shukla V K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shukla V K. Tiotropium: a potential replacement (...) for ipratropium in patients with COPD. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 4 Authors' objectives To summarise the available evidence on tiotropium as a potential replacement for ipratropium in patients with chronic obstructive pulmonary disease. Authors' conclusions - Inhaled tiotropium provides a sustained bronchodilator effect over a 24-hour period in patients with chronic obstructive pulmonary disease (COPD). - There is some evidence that tiotropium 18g once

Health Technology Assessment (HTA) Database.2002

71. Tiotropium for COPD - horizon scanning review

Tiotropium for COPD - horizon scanning review Tiotropium for COPD - horizon scanning review Tiotropium for COPD - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Tiotropium for COPD - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 (...) Authors' objectives To summarise the current research evidence on tiotropium (Spiriva) for chronic obstructive pulmonary disease (COPD). Authors' conclusions - Clinical impact: Tiotropium has shown significant improvements in lung function compared to ipratropium. Clinical trials have also found significant long-term benefits in terms of dyspnoea and health status with a reduction in exacerbations. Tiotropium with its once a day administration may also increase patient compliance. - Service impact

Health Technology Assessment (HTA) Database.2001